Namenda and Repaglinide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Namenda (memantine hydrochloride) and Repaglinide (repaglinide). Common drug interactions include deep vein thrombosis among females and cardiac failure congestive among males.

The phase IV clinical study analyzes what interactions people have when they take Namenda and Repaglinide. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Namenda?

Namenda has active ingredients of memantine hydrochloride. It is often used in dementia. eHealthMe is studying from 14,283 Namenda users. Check the latest studies of Namenda.

What is Repaglinide?

Repaglinide has active ingredients of repaglinide. It is often used in diabetes. eHealthMe is studying from 8,226 Repaglinide users. Check the latest studies of Repaglinide.

On Aug, 02, 2026

17 people who take Namenda and Repaglinide together, and have interactions are studied.

Namenda and Repaglinide drug interactions.

What are the common drug interactions of Namenda and Repaglinide, by gender? *:

female:

Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
Haematoma (collection of blood outside the blood vessels)
Adverse drug reaction
Alopecia (absence of hair from areas of the body)
Chronic kidney disease
Depression
Diarrhoea
Fall
Fatigue (feeling of tiredness)
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)

male:

Cardiac failure congestive
Cardiogenic shock (inadequate circulation of blood)
Hypoglycaemia (deficiency of glucose in the bloodstream)
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
Nasopharyngitis (inflammation of the nasopharynx)
Pneumonia
Sneezing
Thrombocytopenia (decrease of platelets in blood)
Ageusia (loss of taste functions of the tongue)
Anaemia (lack of blood)

What are the common drug interactions of Namenda and Repaglinide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Cardiac failure congestive
Cardiogenic shock (inadequate circulation of blood)
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
Pneumonia
Thrombocytopenia (decrease of platelets in blood)
Adverse drug reaction
Ageusia (loss of taste functions of the tongue)
Alopecia (absence of hair from areas of the body)
Chronic kidney disease
Decreased appetite

What are the existing conditions these people have? *

Hyperkalemia (damage to or disease of the kidney): 6 people, 35.29%
Parkinson's Disease: 2 people, 11.76%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 2 people, 11.76%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 5.88%
Insomnia (sleeplessness): 1 person, 5.88%
Indigestion: 1 person, 5.88%
Hallucinations (sensations that appear real but are created by your mind): 1 person, 5.88%
Circadian Rhythm Sleep Disorder (family of sleep disorders affecting, among other things, the timing of sleep): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Namenda and Repaglinide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously